Dual blockade therapy is currently being trialled for multiple tumour types, but efficacy is variable. Here, the authors use longitudinal proteomics profiling of 22 patients to develop a predictive model of therapy response.
- Jiacheng Lyu
- Lin Bai
- Chen Ding
